Progress of rituximab in the treatment of systemic lupus erythematosus and lupus nephritis
Frontiers in Medicine · 04.10.2024 · 11
DOI: 10.3389/fmed.2024.1472019 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Medicine, online erschienen am 04.10.2024. Verfasst von Shouqi Mo und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Immunology, The First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, China. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with heterogeneous clinical manifestations, often leading to significant morbidity and mortality, particularly due to lupus nephritis (LN). The standard therapeutic approach involving mycophenolate mofetil, cyclophosphamide, and glucocorticoids has shown limitations due to cumulative toxicity and side effects. The introduction of biologic agents, especially rituximab (RTX), a chimeric monoclonal antibody targeting CD20+ B cells, has revolutionized the treatment landscape. This review synthesized the current understanding of B cells’ role in SLE and LN and evaluates RTX’s therapeutic impact. B cells contribute to disease pathogenesis through autoantibody production and immune complex formation, leading to tissue damage. RTX’s mechanisms of action, including Complement-Dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC), and induction of apoptosis, have demonstrated efficacy in both SLE and LN treatment. Clinical studies have reported remission rates and improved renal outcomes with RTX use, although challenges such as human anti-chimeric antibody development and optimal dosing persist. The review emphasized the need for continued research to elucidate RTX’s long-term benefits and risks, and to explore personalized treatment strategies that incorporate B cell biology for better disease management in SLE and LN.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Rheumatology and Immunology, The First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, China.
- Department of Rheumatology, Jieyang People's Hospital, Jieyang, China.
- Department of General Family Medicine, Jieyang People's Hospital, Jieyang, China.
- Jieyang Medical Research Center, Jieyang People's Hospital, Jieyang, China.
- Department of Rheumatology, Shantou University Medical College, Shantou, China.
Zitieren
APA
Mo, S., Li, Y., He, J., & Lin, L. (2024). Progress of rituximab in the treatment of systemic lupus erythematosus and lupus nephritis. Frontiers in Medicine, 11. https://doi.org/10.3389/fmed.2024.1472019
Vancouver
Mo S, Li Y, He J, Lin L. Progress of rituximab in the treatment of systemic lupus erythematosus and lupus nephritis. Frontiers in Medicine. 2024;11. doi:10.3389/fmed.2024.1472019
BibTeX
@article{Mo2024,
author = {Mo, Shouqi and Li, Yilan and He, Junbing and Lin, Ling},
title = {Progress of rituximab in the treatment of systemic lupus erythematosus and lupus nephritis},
journal = {Frontiers in Medicine},
year = {2024},
volume = {11},
doi = {10.3389/fmed.2024.1472019}
}
EUVIMED